Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies-Reference-Cited by-同舟云学术

Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies

Published:2019-02 Issue:3 Volume:29 Page:503-508
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Jacintho Jason D.,Baccei Christopher S.,Bravo Yalda,Broadhead Alex,Chen Austin,Correa Lucia,Fischer Kim,Laffitte Bryan,Lee Catherine,Lorrain Daniel S.,Messmer Davorka,Prasit Peppi,Stebbins Karin J.,Stock Nicholas S.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference20 articles.

1. Identification of the first potent, selective and bioavailable PPARα antagonist

2. Stock, N.S.; Chen, A.C.; Bravo, Y.M.; Jacintho, J.D.; Baccei, J.M.; Stearns, B.A.; Clark, R.C. WO2014/099503 A1.

3. Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma

4. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications;Pharmaceutics;2022-10-08

2. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis;Journal of Medicinal Chemistry;2022-01-21

3. 1,2,4-Triazoles;Comprehensive Heterocyclic Chemistry IV;2022

4. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist;Journal of Medicinal Chemistry;2021-07-27

5. Design and Structural Optimization of Dual FXR/PPARδ Activators;Journal of Medicinal Chemistry;2020-07-20